KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Cash & Equivalents (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Cash & Equivalents for 16 consecutive years, with $33.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 63.91% to $33.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.0 million through Dec 2025, down 63.91% year-over-year, with the annual reading at $33.0 million for FY2025, 63.91% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $33.0 million at Biolife Solutions, up from $29.5 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $91.5 million in Q4 2024, with the low at $19.1 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $42.8 million, with a median of $29.6 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 1290.81% in 2021, then tumbled 72.17% in 2022.
  • Over 5 years, Cash & Equivalents stood at $69.9 million in 2021, then crashed by 72.17% to $19.4 million in 2022, then surged by 43.48% to $27.9 million in 2023, then soared by 228.14% to $91.5 million in 2024, then tumbled by 63.91% to $33.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $33.0 million, $29.5 million, and $31.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.